Triad Business Journal reports a Cary, North Carolina compounder pulled its version of a major diabetes and weight-loss drug after regulatory scrutiny.
Recap by typeshit. Post by Triad Business Journal on X.
Lincoln Journal Star reports FDA advisors are weighing whether seven unapproved peptides can be used in some compounded prescriptions.
MedPro Group points to an HHS move letting pharmacies compound six peptides that lack FDA approval. Details are in the linked story.
The segment covers a federal draft policy that could open access to some injectable peptides, alongside proposed changes to infant formula nutrients.
The longevity researcher argues the FDA system has grown too slow and costly, saying it favors big drugmakers. He offers this as the reason reform efforts emerged.
Mounjaro brought in $10.7 billion and Zepbound $5.4 billion. Lilly says about seven in 10 Medicare Bridge patients use its drugs, while Foundayo hit $184 million.
The telehealth company says it serves nearly 3 million people and is sticking with 2030 targets of at least $6.5 billion in revenue.
Loading…